Table 3 Antidiabetic activity of synthesized compounds
From: Synthesis, SAR and in vitro therapeutic potentials of thiazolidine-2,4-diones
Compound | % inhibition | ||||
|---|---|---|---|---|---|
25 μg/ml | 50 μg/ml | 75 μg/ml | 100 μg/ml | IC50 (μg/ml) | |
1 | 22.65 | 35.79 | 55.52 | 88.68 | 54.35 |
2 | 17.89 | 42.62 | 59.78 | 74.67 | 47.51 |
3 | 29.45 | 47.98 | 60.83 | 95.79 | 43.45 |
4 | 31.26 | 40.65 | 63.93 | 92.61 | 43.63 |
5 | 18.26 | 47.61 | 49.24 | 96.72 | 56.64 |
6 | 33.56 | 49.45 | 50.78 | 97.15 | 37.35 |
7 | 24.72 | 35.71 | 64.87 | 97.15 | 56.09 |
8 | 20.79 | 39.54 | 40.89 | 93.17 | 56.89 |
9 | 24.73 | 53.78 | 68.34 | 89.37 | 41.67 |
10 | 29.34 | 43.98 | 63.36 | 98.14 | 47.49 |
11 | 18.49 | 47.87 | 59.74 | 89.71 | 52.69 |
12 | 27.77 | 53.23 | 62.27 | 79.43 | 27.63 |
13 | 25.74 | 43.89 | 56.76 | 92.72 | 48.45 |
14 | 21.78 | 48.82 | 72.54 | 93.92 | 50.80 |
15 | 32.59 | 51.78 | 66.98 | 81.30 | 22.35 |
16 | 27.52 | 43.73 | 57.27 | 85.23 | 40.92 |
17 | 23.67 | 48.56 | 65.46 | 93.17 | 48.48 |
18 | 18.64 | 45.85 | 65.11 | 95.98 | 56.39 |
19 | 29.33 | 47.77 | 58.34 | 90.86 | 40.01 |
20 | 34.73 | 45.98 | 68.34 | 88.45 | 31.62 |
21 | 21.98 | 47.28 | 70.56 | 74.76 | 38.65 |
Acarabose | 37.35 | 53.45 | 73.25 | 88.57 | 21.44 |